Background：CD161 is also known as NKR-P1A, CLEC5B and KLRB1which plays an inhibitory role on natural killer (NK) cells cytotoxicity.
Activation results in specific acid sphingomyelinase/SMPD1 stimulation with subsequent marked elevation of intracellular ceramide.
Activation also leads to AKT1/PKB and RPS6KA1/RSK1 kinases stimulation as well as markedly enhanced T-cell proliferation induced by anti-CD3.
Acts as a lectin that binds to the terminal carbohydrate Gal-alpha Gal epitope as well as to the N-acetyllactosamine epitope.
Binds also to CLEC2D/LLT1 as a ligand and inhibits NK cell-mediated cytotoxicity as well as interferon-gamma secretion in target cells.
New research shows that genetic inactivation of KLRB1 or antibody-mediated CD161 blockade enhances T cell-mediated killing of glioma cells in vitro and their anti-tumor function in vivo.
KLRB1 and its associated transcriptional program are also expressed by substantial T cell populations in other human cancers.
The reference provides an atlas of T cells in gliomas and highlights CD161 and other NK cell receptors as immunotherapy targets.
仕様
サイズ：100ug
Source：Human CD161, His Tag (CD1-H52H3) is expressed from human 293 cells (HEK293). It contains AA Gln 67 - Ser 225 (Accession # Q12918-1).
Molecule：CD161
Synonyms：CD161, C-type lectin domain family 5 member B, HNKR-P1a, NKR-P1A, Natural killer cell surface protein P1A
Species：Human
Tag：His Tag
Expression Systems：HEK293
Expression Rigeion：Gln 67 - Ser 225
Conjugate：Unconjugated
Accession：NP_002249.1
Molecular Weight：39.3 kDa
Characteristics：This protein carries a polyhistidine tag at the N-terminus. The protein has a calculated MW of 39.3 kDa. The protein migrates as 55-70 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin Level：Less than 1.0 EU per ug by the LAL method.
